14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ELVN vs VOR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ELVN Overall Winner
6-Pillar Tally: ELVN 3 – 2 VOR (1 Tie)
Matrix Metrics: ELVN 4 – 2 VOR
As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ELVN carries a Unified Composite Score of 36.2/100 (SELL) at $47.73 (N/M Forward P/E, 0.0% operating margin), whereas VOR carries 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While VOR currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (4–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs VOR. Trailing 12-month operating profitability (ELVN 0.0% vs VOR 0.0%) and valuation multiples (ELVN N/M vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
VOR Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ELVN vs VOR Key Questions & Quantitative Answers
As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ELVN carries a Unified Composite Score of 36.2/100 (SELL) at $47.73 (N/M Forward P/E, 0.0% operating margin), whereas VOR carries 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VOR currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (4–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
ELVN leads the Growth & Scale pillar: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.
VOR screens cheaper on headline valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus VOR (-125.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.